Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 36565 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: August 24, 2021. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Laura K. Moen, Ph.D., 

Director, Division of Extramural Research 

Activities, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6705 

Rockledge Drive, Room 206–Q, Bethesda, MD 

20892, 301–827–5517, moenl@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nhlbi.nih.gov/meetings/nhlbac/ 

index.htm, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: July 6, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14698 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, July 7, 

2021, 9:00 a.m. to July 8, 2021, 7:00 

p.m., National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 which was 

published in the Federal Register on 

June 10, 2021, FR Doc 2021–12144, 86 

FR 30965. 

This notice is being amended to 

change the meeting date from July 7–8, 

2021 to July 28–29, 2021. The meeting 

time remains the same. The meeting is 

closed to the public. 

Dated: July 6, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14738 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Sleep Disorders Research 

Advisory Board. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Sleep Disorders 

Research Advisory Board. 

Date: August 5, 2021. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: The purpose of this meeting is to 

update the Advisory Board and public 

stakeholders on the progress of sleep and 

circadian research activities across NIH, and 

the activities of professional societies. 

Place: Virtual-Teleconference and 

Zoomgov. 

Telephone Access: 1–666–254–5252 

(Meeting ID: 160 375 9848 Passcode: 558748). 

Virtual Access: Meeting ID: 160 375 9848 

Passcode: 558748, https://nih.zoomgov.com/ 

j/1603759848?pwd=a1ZzMmdSZTJ4WTh

OWDBJQlRqbEYvUT09. 

Contact Person: Marishka Brown, Ph.D., 

SDRAB Executive Secretary, Director, 

National Center on Sleep Disorders Research, 

National Institutes of Health, National Heart, 

Lung, and Blood Institute, Division of Lung 

Diseases, 6705 Rockledge Drive, Suite 407B, 

Bethesda 20892, 301–435–0199, ncsdr@

nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nhlbi.nih.gov/meetings/index.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: July 6, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14699 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: RP2 AAV-Based Gene 

Human Therapy for Ocular Diseases 

and Disorders Including XLRP 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice to PTC 

Therapeutics GT, Inc. located in 100 

Corporate, Middlesex Business Center, 

South Plainfield, NJ 07080. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before July 27, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Hiba Alsaffar, Ph.D., 

Licensing and Patenting Manager at 

(240)-276–5530; or at Email: 

hiba.alsaffar@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

I. United States Provisional Patent 

Application No. 62/131,661 filed Mar. 


khammond on DSKJM1Z7X2PROD with NOTICES
36566 Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 

11, 2015, [HHS Ref. No. E–050–2015–0– 

US–01]; 

II. International Patent Application 

No. PCT/US2016/022072 filed Mar. 11, 

2015, [HHS Reference No. E–050–2015– 

0–PCT–03]; expired 

III. Australian National Stage Patent 

Application No. 2016228751, filed Mar. 

11, 2016, [HHS Ref. No. E–050–2015–0– 

AU–04]; pending 

IV. Canadian National Stage Patent 

Application No. 2979229 filed Mar. 11, 

2016, [HHS Ref. No. E–050–2015–0– 

CA–05]; pending 

V. European national Stage Patent 

Application No. 1662623.3 filed Oct. 11, 

2016, [HHS Ref. No. E–050–2015–0–EP– 

06]; issued (validated in DE, FR and GB) 

VI. U.S. national Stage Patent 

Application No. 15/556,746 filed Sep. 8, 

2017 [HHS Ref. No. E–050–2015–0–US– 

08]; issued 

VII. Japanese National Stage Patent 

Application No. 2017–547425 filed Sep. 

8, 2017 [HHS Ref. No. E–050–2015–0– 

JP–07]; pending 

VIII. Divisional European Patent 

Application No. 20176667.2 filed May 

26, 2020 [HHS Ref. No. E–050–2015–0– 

EP–13]; pending 

IX. Divisional Japanese Patent 

Application No. 2020–167984 filed Oct. 

2, 2020 [HHS Ref. No. E–050–2015–0– 

JP–14]; pending 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to: 

‘‘Development and commercialization 

of RP2 AAV-based gene human therapy 

for any ocular disease, disorder or 

condition, including human X-linked 

retinitis pigmentosa (XLRP)’’. 

This technology discloses AdenoAssociated Viral (AAV) vectors 

comprising nucleotide sequences 

encoding RP2 or RPGR- ORF 15 

transgenes and their use in treating or 

preventing X-linked forms of retinitis 

pigmentosa (XLRP). 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: July 2, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–14682 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Motor function in healthy and 

clinical populations. 

Date: August 3, 2021. 

Time: 1:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Maribeth Champoux, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3170, 

MSC 7848, Bethesda, MD 20892, 301–594– 

3163, champoum@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: July 6, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14697 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Integrative Health; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council for Complementary and 

Integrative Health. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

The meeting will be held as a virtual 

meeting and is open to the public as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. The Open Session will 

be open to the public via NIH Videocast. 

The URL link to access this meeting is 

https://videocast.nih.gov. 

Name of Committee: National Advisory 

Council for Complementary and Integrative 

Health. 

Date: September 10, 2021. 

Closed: 10:00 a.m. to 11:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Democracy 2, 6707 Democracy Boulevard, 

Bethesda, MD 20817 (Virtual Meeting). 

Open: 11:40 a.m. to 5:00 p.m. 

Agenda: A report from the Director of the 

Center and Other Staff. 

Place: National Institutes of Health, 

Democracy 2, 6707 Democracy Boulevard, 

Bethesda, MD 20817 (Virtual Meeting). 

Contact Person: Partap Singh Khalsa, 

Ph.D., DC, Director, Division of Extramural 

Activities, National Center for 

Complementary and Integrative Health, 

National Institutes of Health, 6707 

Democracy Blvd., Suite 401, Bethesda, MD 

20892–5475, 301–594–3462, khalsap@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 


khammond on DSKJM1Z7X2PROD with NOTICES